Clinical trials: Tislelizumab
Gastric Junction Adenocarcinoma, Gastric Cancer
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
The goal of this clinical trial is to learn if sorbitol works to enhance the therapeutic effect of neoadjuvant chemotherapy combined with Tirellizumab (PD-1 inhibitor) in patients with locally advanced gastric cancer.
- Conditions
- Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy, Neoadjuvant Therapies
- Trial name
- SNCCTGC (NCT06826079)
- Testing
- Sorbitol + PD-1 inhibitor + SOX chemotherapy, PD-1 inhibitor + SOX chemotherapy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Glioblastoma Multiforme
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
The goal of this clinical trial is To investigate the safety and efficacy of Tumor-Treating Fields (TTFields) in combined with temozolomide (TMZ) and tislelizumab in the treatment of newly diagnosed glioblastoma (GBM).
- Trial name
- NCT06353360
- Testing
- Tumor Treating Fields, Tislelizumab, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer
This is a single-arm interventional study targeting patients with initially unresectable MSS-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis.
- Trial name
- NCT07512674
- Testing
- Receiving lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy and bevacizumab targeted therapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Unresectable Hepatocellular Carcinoma
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
This is a prospective, non-randomized, open-label, single-center phase II clinical trial. It aims to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (DST) to guide…
- Trial name
- NCT07351513
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Volunteers
- 94 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Radiotherapy
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
PD-1 inhibitor plus anti-VEGFR has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, PD-1 Inhibitors
- Trial name
- NCT06708650
- Testing
- Combination of SFRT, PD-L1 inhibitor, and Anti-VEGF
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guiping People's Hospital
Esophageal Squamous Cell Carcinoma
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma
This is a open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of IPM514 in patients with esophageal squamous cell carcinoma.
- Trial name
- NCT06690476
- Testing
- Dose escalation(IPM514 monotherapy), Dose expansion (IPM514 combined with tislelizumab), Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Peking University
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of immunotherapy (Tislelizumab), targeted therapy (Cetuximab), with chemotherapy (Cisplatin and Nab-paclitaxel) as a possible…
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Resectable Oral and Oropharyngeal Squamous Cell Carcinoma, Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
- Trial name
- OSCC (NCT06728618)
- Testing
- Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Zhongshan Hospital
Lung Cancer (Locally Advanced or Metastatic)
The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer
To determine the optimal objective response rate (ORR) of tislelizumab combined with albumin-bound paclitaxel and platinum agents in patients with KRAS-mutant lung cancer who are ineligible for curative surgery
- Trial name
- NCT07638878
- Testing
- tislelizumab in combination with nab-paclitaxel and platinum chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Medical University
Rectal Cancer
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer
The study is designed to test the hypothesis that the clinical complete response (CCR) rate of patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy will increase after an adaptive-design…
- Trial name
- NCT04443543
- Testing
- Capecitabine (Xeloda) Pharmacogenetic Test Reagents, irinotecan, IMRT
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have…
- Trial name
- NCT06259721
- Testing
- Anti-PD1 antibody, nimotuzumab and capecitabine
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Ureteral Cancer, Neoadjuvant Therapy
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
This study is designed as an open-label, single-arm, single-center, phase II clinical trial, aiming to evaluate the efficacy and safety of neoadjuvant Tislelizumab combined with Nab-Paclitaxel followed by distal ureterectomy for…
- Conditions
- Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor, Kidney-sparing
- Trial name
- NCT07125547
- Testing
- PD-1 inhibitior, Nab-paclitaxel, distal ureterectomy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Second Hospital
Non Small Cell Lung Cancer
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
This study aims to investigate the efficacy and safety of fecal microbiota transplantation (FMT) as a treatment for non-small cell lung cancer (NSCLC) patients whose disease has progressed after immune checkpoint inhibitor (ICI)…
- Trial name
- FMT-LUNG (NCT07432984)
- Testing
- Tislelizumab, Fecal Microbiota Transplant(FMT)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Se-Hoon Lee
Intrahepatic Cholangiocarcinoma
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Evaluating the efficacy and safety of treatment with Tislelizumab in combination with S-1 in patients with high-risk recurrent intrahepatic cholangiocarcinoma after radical surgery
- Trial name
- NCT06664021
- Testing
- Tislelizumab combined with S-1
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Recurrent Nasopharyngeal Carcinoma
Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
The purpose of this study is to compare chemotherapy plus immunotherapy with immunochemotherapy combined subsequent locoregional radiotherapy in recurrent nasopharyngeal carcinoma (NPC), in order to confirm the value of…
- Trial name
- NCT07088484
- Testing
- ICI-chemotherapy and LIMT
- Volunteers
- 50 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Triple-negative Breast Cancer
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of surufatinib combined with tislelizumab in the treatment of metastatic triple-negative breast cancer (TNBC).
- Trial name
- NCT05746728
- Testing
- Surufatinib, Tislelizumab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Huihua Xiong
Carcinoma, Intrahepatic Cholangiocarcinoma
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with surufatinib and tislelizumab in the first line treatment of patients with unresectable or metastatic biliary tract cancer
- Conditions
- Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer, Surufatinib
- Trial name
- NCT06134193
- Testing
- HAIC, Surufatinib, Tislelizumab
- Volunteers
- 41 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic…
- Trial name
- NCT06331845
- Testing
- Gemcitabine, Cisplatin, Paclitaxel protein-bound
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Advanced or Recurrent Solid Tumors
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) .
- Trial name
- NCT06541639
- Testing
- EVM16, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Peking University
Pancreatic Cancer
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
The goal of this Single Arm Phase Ib clinical trial is to test standard of care chemotherapy and anti PD1 and IL1b to evaluate the safety and preliminary toxicity of this quadruplet regimen prior to resection in patients with…
- Trial name
- NCT05984602
- Testing
- Canakinumab, Tislelizumab, Nab-Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- NYU Langone Health
Solid Tumor
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with…
- Trial name
- NCT06349837
- Testing
- Tislelizumab, Low Dose Radiotherapy, Stereotactic Ablative Radiotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sichuan University